[
  {
    "ts": "2025-12-05T03:09:50+00:00",
    "headline": "AbCellera Biologics Inc (ABCL) Down 23% Since Q3 2025 Results",
    "summary": "​AbCellera Biologics Inc. (NASDAQ:ABCL) is one of the Best Up and Coming Canadian Stocks to Buy. AbCellera Biologics Inc. (NASDAQ:ABCL) is down more than 23% since its fiscal Q3 2025 business update on November 6. However, Wall Street maintains a bullish sentiment with analysts’ 12-month average price target of $8.5, reflecting 144.96% upside from the […]",
    "url": "https://finance.yahoo.com/news/abcellera-biologics-inc-abcl-down-030950330.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "adb93b8f-dbd3-3aba-bd7e-23c45cbe6653",
      "content": {
        "id": "adb93b8f-dbd3-3aba-bd7e-23c45cbe6653",
        "contentType": "STORY",
        "title": "AbCellera Biologics Inc (ABCL) Down 23% Since Q3 2025 Results",
        "description": "",
        "summary": "​AbCellera Biologics Inc. (NASDAQ:ABCL) is one of the Best Up and Coming Canadian Stocks to Buy. AbCellera Biologics Inc. (NASDAQ:ABCL) is down more than 23% since its fiscal Q3 2025 business update on November 6. However, Wall Street maintains a bullish sentiment with analysts’ 12-month average price target of $8.5, reflecting 144.96% upside from the […]",
        "pubDate": "2025-12-05T03:09:50Z",
        "displayTime": "2025-12-05T03:09:50Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/d8aa5528592f9f99843e04fe1078703c",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zW1JJ7XEpYRC0VZGRZvqLA--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/d8aa5528592f9f99843e04fe1078703c.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/6qZ5DcPMBp6HbJc1y1KG.Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/d8aa5528592f9f99843e04fe1078703c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/abcellera-biologics-inc-abcl-down-030950330.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/abcellera-biologics-inc-abcl-down-030950330.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABCL"
            },
            {
              "symbol": "TFC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-05T03:14:11+00:00",
    "headline": "Why Analysts See On’s Story Evolving Amid Strong Results But Increasing Valuation Risks",
    "summary": "On Holding's fair value estimate has been nudged up to about $61.40 per share from roughly $61.29, even as the modeled discount rate edges higher to around 8.21 % from about 8.19 % and revenue growth expectations ease slightly to roughly 22.04 % from near 22.10 %. This fine tuning reflects a tug of war between resilient fundamental momentum that supports a higher valuation anchor and a more demanding market backdrop that warrants slightly tighter assumptions. Read on to see how these shifting...",
    "url": "https://finance.yahoo.com/news/why-analysts-see-story-evolving-031411985.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "8a91908e-8d95-3fa4-816f-c2ae60e3edf2",
      "content": {
        "id": "8a91908e-8d95-3fa4-816f-c2ae60e3edf2",
        "contentType": "STORY",
        "title": "Why Analysts See On’s Story Evolving Amid Strong Results But Increasing Valuation Risks",
        "description": "",
        "summary": "On Holding's fair value estimate has been nudged up to about $61.40 per share from roughly $61.29, even as the modeled discount rate edges higher to around 8.21 % from about 8.19 % and revenue growth expectations ease slightly to roughly 22.04 % from near 22.10 %. This fine tuning reflects a tug of war between resilient fundamental momentum that supports a higher valuation anchor and a more demanding market backdrop that warrants slightly tighter assumptions. Read on to see how these shifting...",
        "pubDate": "2025-12-05T03:14:11Z",
        "displayTime": "2025-12-05T03:14:11Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/044527dc303068ac9ca156aafbedfd45",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/7muOZZMsFoj5q1.z_x6oRw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/044527dc303068ac9ca156aafbedfd45.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ihmvFc0vgtTixj3ZvLfncg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/044527dc303068ac9ca156aafbedfd45.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/why-analysts-see-story-evolving-031411985.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-analysts-see-story-evolving-031411985.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ONON"
            },
            {
              "symbol": "TFC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]